New Treatment for Gastrointestinal Tumors Now Available at Hartford Hospital

Print icon

Hartford HealthCare cancer specialists have delivered a new and exciting therapy to treat patients diagnosed with gastrointestinal neuroendocrine tumors, a relatively rare form of cancer. Dr. Andrew Salner is a radiation oncologist and Medical Director of the Hartford HealthCare Cancer Institute at Hartford Hospital

Q: What are gastrointestinal neuroendocrine tumors?

A: These are a relatively rare group of tumors that arise from cells that have specific hormone producing functions in the body. The abdominal neuroendocrine tumors arise in the stomach, small intestine, appendix, large intestine and pancreas.  They are also called carcinoid tumors, and can in selected patients cause carcinoid syndrome characterized by flushing, sweats and diarrhea.  They tend to grow slowly though they vary in their level of malignancy, and can ultimately spread to other parts of the body.

Q: How does this new treatment – which involves radiation – work in the body? 

A: These tumors, if localized can be removed by surgery. If more advanced, they have been a conundrum in that we can block some of the abnormal hormone production with medications to lessen symptoms but don’t have a good tumor shrinking therapy.  Conventional chemotherapy agents do not work effectively.  This new therapy, lutathera, consist of 2 parts, one that specifically binds to the receptor on the cancer cell, and the other is the radioactive molecule that delivers a potentially lethal punch to the cancer cell only.

Administration of this drug can be complicated. It is administered intravenously, but can injure the kidneys if not delivered with a protective amino acid IV solution and with a set of antinausea medications as well. It takes a team of infusion nurses, pharmacists, nuclear medicine and radiation safety staff to do give the 6-8 hour therapy well.

Q: Is it likely that other drugs like this will emerge for other tumor types?   

A: This new class of drugs, Peptide Receptor Radionuclide Therapy, or PRRT, already has new agents in testing that target other types of cancer cells. I am extremely optimistic that this drug opens a door for new and exciting cancer therapies for patients otherwise challenging to treat effectively.

For more information about cancer care services at the Hartford HealthCare Cancer Institute at Hartford Hospital, call 1-855-255-6181, or click here

What's New


Why People, And Medical Researchers, Need Help with Anger

Anger is the first negative emotion babies can express and research shows that as many people seek treatment for it as depression and anxiety combined. Yet it is not officially classified a mental health disorder which, according to Dr. Ray DiGuiseppe, director of education with the Albert Ellis Institute and...

High Preparedness: Legal or Not, What’s Weed Do to Drivers?

Dr. Godfrey Pearlson Director, Olin Neuropsychiatry Research Center at the Institute of Living Research Director, Institute of Living Hartford HealthCare Behavioral Health Network Whatever the outcome of the current debate on legalizing recreational marijuana in Connecticut, we need to know more about marijuana’s overall effect on the brain and behavior...

Stress and Your Heart

Study: Stress-Related Disorder Heightens Heart Risk

People have a 60 percent increased risk of cardiovascular disease within the first year of being diagnosed with any stress-related disorder, according to a new study in Sweden. The results, published April 10 in the British Medical Journal, used data from the Swedish National Patient Register to compare people diagnosed...

Joint Replacement Surgery

Why a Partial Knee Replacement is Same-Day Surgery

Doctors at the Hartford HealthCare Bone & Joint Institute at Hartford Hospital are using new technology to customize joint replacements, making recovery easier. Here’s more from Dr. Mark Shekhman, a Bone & Joint Institute orthopedic surgeon: Q: At the bone and joint institute you use tools to assess the best route...